Vertebrate cells can die by either an accidental cell death or a regulated cell death. Accidental cell death is a biologically uncontrolled process, whereas regulated cell death involves tightly structured signaling cascades and molecularly defined effector mechanisms. Regulated cell death may occur in multiple forms in response to different stresses, in this case from exposure to a drug and radiation.

The IGV-001 process is designed to do many things at once as it draws the invasion of the innate immune system to the site of implantation. First, a surgical wound draws an immune response, amplified by the presence of a foreign body, in this case a plastic biodiffusion chamber. IMV-001 silences immunosuppressive cells both inside the chamber and outside, while microvesicles laden with tumor antigens diffuse out of the chambers, intended to trigger a broad anti-tumor immune response. Since the chamber is formulated with an additional amount of IMV-001 designed to diffuse out of the chamber, antigen release is accompanied by free unbound IMV-001. IMV-001 with its intrinsic dinucleotide CpG motif, serves as an adjuvant to further stimulate the innate immune response. Specifically, IMV-001 is intended to promote antigen uptake and stimulate a pro-inflammatory response in plasmacytoid DC cells that mature and traffic when activated through lymphatic vessels to the nearest lymph nodes.

Here’s how we do it:

Step 1:  Patient Cell Harvest, Treatment, and Implant

Step 2:  Immunogenic Cell Death, Patient-Specific Antigens, Innate Immune System Activation

Step 3:  Long-term Adaptive Immune Activation and Response